Current and future therapeutic options for chronic hepatitis D virus infection
In the last few years there have been innovations in HDV therapy which have brought new excitement in the scientific community also considering the few therapeutic opportunities. Recently, new molecular targets have been identified, both in monotherapy and in combination with peginterferon alpha (Pe...
Saved in:
Main Authors: | Mariantonietta Pisaturo, Antonio Russo, Pierantonio Grimaldi, Salvatore Martini, Nicola Coppola |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-02-01
|
Series: | Frontiers in Cellular and Infection Microbiology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcimb.2024.1382017/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Molecular Epidemiology, Drug-Resistant Variants, and Therapeutic Implications of Hepatitis B Virus and Hepatitis D Virus Prevalence in Nigeria: A National Study
by: Oludare ‘Sunbo Adewuyi, et al.
Published: (2025-01-01) -
Hepatitis D virus infection triggers CXCL9-11 upregulation in hepatocytes and liver infiltration of CXCR3+ CD4 T cells
by: Jan-Hendrik Bockmann, et al.
Published: (2025-03-01) -
Is Combined Bulevirtide and Pegylated Interferon Therapy for Chronic Hepatitis D Superior over Bulevirtide Monotherapy?
by: V. E. Syutkin, et al.
Published: (2020-09-01) -
Lack of Tissue Virological Response as a Predictor of Relapse in Chronic Hepatitis D after Completion Bulevirtide Therapy
by: P. O. Bogomolov, et al.
Published: (2024-12-01) -
Virus Variability and Its Impact on HIV and Hepatitis Therapy
by: Domenico Genovese, et al.
Published: (2012-01-01)